Ignite Creation Date:
2025-12-24 @ 2:41 PM
Ignite Modification Date:
2026-02-04 @ 5:57 AM
Study NCT ID:
NCT01180959
Status:
COMPLETED
Last Update Posted:
2022-11-07
First Post:
2010-08-11
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy
Sponsor:
M.D. Anderson Cancer Center
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Liver Cancer | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Advanced Liver Cancer | View |
| None | primary neoplasm of the liver | View |
| None | Erlotinib | View |
| None | Bevacizumab | View |
| None | Hepatocellular Carcinoma | View |
| None | HCC | View |
| None | Avastin | View |
| None | Anti-VEGF monoclonal antibody | View |
| None | rhuMAb-VEGF | View |
| None | OSI-774 | View |
| None | Tarceva | View |